The Expert Committee recommended the addition of the monoclonal antibodies ansuvimab and atoltivimab + maftivimab + odesivimab to the core list of the EML and EMLc for the treatment of confirmed Ebola virus disease caused by Zaire ebolavirus in adults and children, and in neonates of unconfirmed infection status aged 7 days old or younger, born to mothers with confirmed infection. The Committee noted that Ebola virus disease is a life-threatening disease with a high case-fatality rate, for which effective treatments are of public health importance. The Committee considered that the available clinical trial evidence for ansuvimab and atoltivimab + maftivimab + odesivimab has demonstrated important reductions in mortality compared to standard supportive care alone. The Committee considered that their inclusion on the Model Lists would represent a strong equity and advocacy message, fully aligned with WHO guidelines, that could contribute to broader actions being undertaken to ensure reliable, affordable access to quality-assured therapeutics for Ebola virus disease.